(Q38460250)

English

Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?

scientific article published on September 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 September 2017

Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer? (English)

1 reference

Europe PubMed Central

3 September 2017

1 reference

ORCID Public Data File 2021

author name string

K Jung

1

1 reference

Europe PubMed Central

3 September 2017

C Stephan

2

1 reference

Europe PubMed Central

3 September 2017

U Elgeti

3

1 reference

Europe PubMed Central

3 September 2017

M Lein

4

1 reference

Europe PubMed Central

3 September 2017

B Brux

5

1 reference

Europe PubMed Central

3 September 2017

G Kristiansen

6

1 reference

Europe PubMed Central

3 September 2017

B Rudolph

7

1 reference

Europe PubMed Central

3 September 2017

S Hauptmann

8

1 reference

Europe PubMed Central

3 September 2017

D Schnorr

9

1 reference

Europe PubMed Central

3 September 2017

S A Loening

10

1 reference

Europe PubMed Central

3 September 2017

P Sinha

11

1 reference

Europe PubMed Central

3 September 2017

language of work or name

0 references

publication date

1 September 2001

1 reference

Europe PubMed Central

3 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

3 September 2017

93

1 reference

Europe PubMed Central

3 September 2017

759-765

1 reference

Europe PubMed Central

3 September 2017

5

1 reference

Europe PubMed Central

3 September 2017

Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Adding free to total prostate-specific antigen levels in trials of prostate cancer screening

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Radical prostatectomy: consideration of the risk factors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Lowering PSA cutoffs to enhance detection of curable prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Comparison of the Clinical Validity of Free Prostate–Specific Antigen, Alpha–1 Antichymotrypsin–Bound Prostate–Specific Antigen and Complexed Prostate–Specific Antigen in Prostate Cancer Diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Factors influencing the ratio of free to total prostate-specific antigen in serum

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Role of PSA and its indices in determining the need for repeat prostate biopsies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

The appropriate lower limit for the percent free prostate-specific antigen reflex range

1 reference

https://api.crossref.org/works/10.1002%2FIJC.1393

21 January 2018

Identifiers

10.1002/IJC.1393

1 reference

Europe PubMed Central

3 September 2017

release_oc6d4tyf3nad7ctdd3g736v63y

1 reference

https://api.fatcat.wiki/v0/release/oc6d4tyf3nad7ctdd3g736v63y

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38460250&oldid=2046628157"